{"organizations": [], "uuid": "bfb07f31295ea882a6af5bd9c36bb44c7ff2ce49", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tesaro-says-topacio-data-demonstra/brief-tesaro-says-topacio-data-demonstrates-compelling-clinical-activity-of-zejula-in-patients-with-type-of-ovarian-cancer-idUSASC09TNT", "country": "US", "domain_rank": 408, "title": "BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.185, "site_type": "news", "published": "2018-03-27T04:12:00.000+03:00", "replies_count": 0, "uuid": "bfb07f31295ea882a6af5bd9c36bb44c7ff2ce49"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tesaro-says-topacio-data-demonstra/brief-tesaro-says-topacio-data-demonstrates-compelling-clinical-activity-of-zejula-in-patients-with-type-of-ovarian-cancer-idUSASC09TNT", "ord_in_thread": 0, "title": "BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer", "locations": [], "entities": {"persons": [{"name": "topacio", "sentiment": "negative"}], "locations": [{"name": "zejula", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "tesaro inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Tesaro Inc:\n* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER\n* TESARO INC - ‍EFFICACY OF NIRAPARIB IN COMBINATION WITH AN ANTI-PD-1 MAB SURPASSES HISTORICAL EFFICACY BENCHMARKS FOR PD-1 OR PARP MONOTHERAPIES​\n* TESARO INC - COMBINATION OF NIRAPARIB WITH PEMBROLIZUMAB WAS WELL TOLERATED WITH AN INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA OF 9%\n* TESARO-POTENTIAL APPROACH TO REDUCE INCIDENCE OF GRADE 3 OR 4 THROMBOCYTOPENIA IDENTIFIED BASED ON RETROSPECTIVE ANALYSIS OF DATA FROM PHASE 3 NOVA TRIAL\n* TESARO - IN ADDITION TO THROMBOCYTOPENIA, OTHER MOST COMMONLY OBSERVED GRADE ≥3 ADVERSE EVENTS N STUDY INCLUDED ANEMIA AND NEUTROPENIA Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T04:12:00.000+03:00", "crawled": "2018-03-27T11:54:17.000+03:00", "highlightTitle": ""}